Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.52 |
| ▸ | MDH1 | P40925 | 1/20 | 0.47 |
| ▸ | MDH2 | P40926 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4953381 | 0.89 | ALDH1A1 (0.56) | ENPP2PDK2MEN1KMT2ATSHR | |
| SCHEMBL4949410 | 0.89 | FKBP1A (0.52) | ENPP2MEN1KMT2ALMNAMAPT | |
| SCHEMBL4951646 | 0.88 | MEN1 (0.58) | MEN1KMT2ALMNAHTTOPRM1 | |
| SCHEMBL4951152 | 0.86 | HTR1A (0.55) | ENPP2MEN1KMT2ALMNAMAPT | |
| SCHEMBL4953715 | 0.86 | MAPT (0.54) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL4952232 | 0.86 | GHSR (0.57) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL13994626 | 0.86 | MEN1 (0.47) | MEN1KMT2ALMNAOPRM1OPRK1 | |
| SCHEMBL13994637 | 0.85 | PARP1 (0.43) | ENPP2PDK2MEN1KMT2ALMNA | |
| SCHEMBL4953825 | 0.85 | PARP1 (0.43) | ENPP2PDK2MEN1KMT2ALMNA | |
| SCHEMBL4951161 | 0.84 | FKBP1A (0.54) | MEN1KMT2ALMNAMAPTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | KOWA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | KOWA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | KOWA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | HSD11B1, HSD11B2, HSD3B1 | ENPP2 3541/4885MDH1 377/4885MDH2 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.